Found: 8
Select item for more details and to access through your institution.
Randomized, Blinded, Placebo- and Positive-Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 1, p. 22, doi. 10.1002/cpdd.352
- By:
- Publication type:
- Article
The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 1, p. e12, doi. 10.1111/bjh.17999
- By:
- Publication type:
- Article
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 4, p. 994, doi. 10.1111/bcp.13037
- By:
- Publication type:
- Article
Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products—a Meeting Report.
- Published in:
- AAPS Journal, 2024, v. 26, n. 1, p. 1, doi. 10.1208/s12248-023-00884-5
- By:
- Publication type:
- Article
Clinical Endpoint Bioequivalence Studies Are Not Sensitive: A Perspective From Generic Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 2, p. 295, doi. 10.1002/cpt.1244
- By:
- Publication type:
- Article
Establishing the suitability of model‐integrated evidence to demonstrate bioequivalence for long‐acting injectable and implantable drug products: Summary of workshop.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 5, p. 624, doi. 10.1002/psp4.12931
- By:
- Publication type:
- Article
Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 5, p. 585, doi. 10.1002/psp4.12907
- By:
- Publication type:
- Article
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 3, p. 533, doi. 10.1007/s00277-021-04728-0
- By:
- Publication type:
- Article